The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Sam S. Chang MD, MBA, discusses intravesical mitomycin in low-grade intermediate-risk nonmuscle-invasive bladder cancer vs ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

Michael Green, PhD, discusses a new method of assessing lymphoma subtypes utilizing the tumor microenvironment.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

A panelist discusses a typical lower-risk myelodysplastic syndrome case managed with luspatercept over ...

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.

A panelist discusses the evolving role of luspatercept in low-risk myelodysplastic syndrome, highlighting its broad efficacy beyond SF3B1 mutations, its advantage in reducing transfusions and ...

An expert highlights that the future of metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing with novel drug classes such as radioligand therapies, proteolysis-targeting ...